[go: up one dir, main page]

EE04091B1 - Koostised ja meetodid silmasisese rõhu alandamiseks - Google Patents

Koostised ja meetodid silmasisese rõhu alandamiseks

Info

Publication number
EE04091B1
EE04091B1 EEP199900410A EEP9900410A EE04091B1 EE 04091 B1 EE04091 B1 EE 04091B1 EE P199900410 A EEP199900410 A EE P199900410A EE P9900410 A EEP9900410 A EE P9900410A EE 04091 B1 EE04091 B1 EE 04091B1
Authority
EE
Estonia
Prior art keywords
compositions
methods
intraocular pressure
reducing intraocular
reducing
Prior art date
Application number
EEP199900410A
Other languages
English (en)
Estonian (et)
Inventor
Flinn Peacock Regina
Warren Reed Kenneth
Yen Shau-Fong
Sou Mary
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04091(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of EE9900410A publication Critical patent/EE9900410A/xx
Publication of EE04091B1 publication Critical patent/EE04091B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
EEP199900410A 1997-03-17 1998-03-13 Koostised ja meetodid silmasisese rõhu alandamiseks EE04091B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17
PCT/EP1998/001483 WO1998041208A1 (en) 1997-03-17 1998-03-13 Compositions and methods for reducing ocular hypertension

Publications (2)

Publication Number Publication Date
EE9900410A EE9900410A (et) 2000-04-17
EE04091B1 true EE04091B1 (et) 2003-08-15

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900410A EE04091B1 (et) 1997-03-17 1998-03-13 Koostised ja meetodid silmasisese rõhu alandamiseks

Country Status (32)

Country Link
EP (1) EP0969846B2 (xx)
JP (2) JP4920124B2 (xx)
KR (1) KR100555818B1 (xx)
CN (1) CN1236775C (xx)
AR (2) AR002194A1 (xx)
AT (1) ATE257385T1 (xx)
AU (1) AU738781B2 (xx)
BR (2) BRPI9816218B1 (xx)
CA (1) CA2280089C (xx)
CL (1) CL2009001870A1 (xx)
CO (1) CO4940427A1 (xx)
CY (1) CY2526B1 (xx)
CZ (1) CZ299833B6 (xx)
DE (1) DE69820997T3 (xx)
DK (1) DK0969846T4 (xx)
EE (1) EE04091B1 (xx)
ES (1) ES2214706T5 (xx)
HU (1) HU228896B1 (xx)
ID (1) ID22389A (xx)
IL (1) IL131041A0 (xx)
MY (1) MY122237A (xx)
NO (1) NO327713B1 (xx)
NZ (1) NZ337322A (xx)
PE (1) PE61899A1 (xx)
PL (1) PL197509B1 (xx)
PT (1) PT969846E (xx)
RU (1) RU2197970C2 (xx)
SI (1) SI0969846T2 (xx)
TW (1) TW527187B (xx)
UA (1) UA63938C2 (xx)
WO (1) WO1998041208A1 (xx)
ZA (1) ZA982188B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
TWI290470B (en) 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
WO2002022131A1 (fr) * 2000-09-13 2002-03-21 Santen Pharmaceutical Co., Ltd. Collyre
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
ATE442849T1 (de) * 2004-03-18 2009-10-15 R Tech Ueno Ltd Wässrige zusammensetzung mit einem thiazol- derivat
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
ES2460967T3 (es) * 2005-08-02 2014-05-16 Santen Pharmaceutical Co., Ltd. Método para la prevención de la degradación de una sustancia térmicamente inestable
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
WO2007105691A1 (ja) * 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. 水性組成物
CN101420934B (zh) * 2006-03-17 2014-03-19 庄臣及庄臣视力保护公司 用于使氧化不稳定的组合物稳定的方法
KR20090082401A (ko) * 2006-10-31 2009-07-30 알콘 리서치, 리미티드 안 질환 치료용 ｐａｉ－１ 결합 조절제
US20100120908A1 (en) * 2007-02-07 2010-05-13 Teika Pharmaceutical Co., Ltd Eye drop preparation comprising latanoprost
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
JP5640207B2 (ja) * 2007-10-08 2014-12-17 セラオプティクスＴｈｅｒａｏｐｔｉｃｓ 水性眼用処方物
EP2420223B1 (en) * 2008-03-17 2017-07-19 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CA2830896A1 (en) * 2011-04-12 2012-10-18 Yukihiko Mashima Aqueous ophthalmic composition
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
CN104114152A (zh) 2011-12-07 2014-10-22 阿勒根公司 用盐敏性乳液体系对人泪液膜进行有效脂质递送
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
KR102487299B1 (ko) 2014-11-25 2023-01-10 알러간, 인코포레이티드 안정화된 오메가-3 안과용 조성물
CN113164043B (zh) * 2018-09-21 2024-10-22 奥夫博医疗创新有限公司 用于青光眼的组合物和方法
US11312922B2 (en) 2019-04-12 2022-04-26 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner comprising a sulfonic acid-containing surfactant and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458587B1 (en) * 1990-05-22 1993-07-14 R-Tech Ueno Ltd. Synergistic combination for ophthalmic use
AU1427592A (en) * 1991-02-07 1992-09-07 Allergan, Inc. 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
WO1995030420A1 (en) * 1994-05-06 1995-11-16 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
NZ337322A (en) 2001-05-25
SI0969846T1 (en) 2004-06-30
NO994481D0 (no) 1999-09-16
PL197509B1 (pl) 2008-04-30
ES2214706T5 (es) 2011-02-02
EP0969846B1 (en) 2004-01-07
ID22389A (id) 1999-10-07
HU228896B1 (en) 2013-06-28
AR002194A1 (es) 1998-01-07
KR100555818B1 (ko) 2006-03-03
TW527187B (en) 2003-04-11
HUP0002194A2 (hu) 2000-12-28
DK0969846T4 (da) 2010-12-20
RU2197970C2 (ru) 2003-02-10
SI0969846T2 (sl) 2010-12-31
CA2280089A1 (en) 1998-09-24
DK0969846T3 (da) 2004-04-13
DE69820997T3 (de) 2011-10-06
EP0969846B2 (en) 2010-08-25
CY2526B1 (en) 2006-02-08
CN1236775C (zh) 2006-01-18
EP0969846A1 (en) 2000-01-12
CA2280089C (en) 2009-03-03
EE9900410A (et) 2000-04-17
AU738781B2 (en) 2001-09-27
ZA982188B (en) 1998-09-17
HUP0002194A3 (en) 2012-08-28
UA63938C2 (uk) 2004-02-16
CZ325799A3 (cs) 2000-01-12
NO994481L (no) 1999-09-16
ATE257385T1 (de) 2004-01-15
AU7035398A (en) 1998-10-12
BR9808016A (pt) 2000-03-08
IL131041A0 (en) 2001-01-28
AR011192A1 (es) 2000-08-02
CO4940427A1 (es) 2000-07-24
WO1998041208A1 (en) 1998-09-24
CN1249687A (zh) 2000-04-05
HK1026841A1 (en) 2000-12-29
MY122237A (en) 2006-04-29
CZ299833B6 (cs) 2008-12-10
JP2001515502A (ja) 2001-09-18
DE69820997T2 (de) 2004-12-09
JP2010043110A (ja) 2010-02-25
PE61899A1 (es) 1999-06-30
DE69820997D1 (de) 2004-02-12
NO327713B1 (no) 2009-09-14
PT969846E (pt) 2004-05-31
PL335168A1 (en) 2000-04-10
CL2009001870A1 (es) 2010-01-22
JP4920124B2 (ja) 2012-04-18
BRPI9816218B1 (pt) 2016-04-12
KR20000076330A (ko) 2000-12-26
ES2214706T3 (es) 2004-09-16

Similar Documents

Publication Publication Date Title
EE04091B1 (et) Koostised ja meetodid silmasisese rõhu alandamiseks
DE69726189D1 (de) Mikrokeratom
DE69630221D1 (de) Stabile alkoholisch-wässrige zusammensetzung
FR2751867B1 (fr) Prothese collerette
DE69503381D1 (de) Kniegelenkendoprothese
DE59507573D1 (de) Implantat
FI951184L (fi) Taikinaa sisältävä yhdistelmä sekä menetelmä sen valmistamiseksi
DE69526966D1 (de) Hautkräftigende kometische zusammensetzung
DK0821920T4 (da) Stent
FI101933B1 (fi) Nivelproteesi
FR2724108B1 (fr) Prothese articulaire
DK0991658T3 (da) Dolastatin 15-derivater
FI954773A7 (fi) Antihypertriglyserideeminen koostumus
BR9606809A (pt) Composição inseticidamente ativa
BR9607058A (pt) Composição
PT728814E (pt) Composicao betuminosa
BR9609903A (pt) ComposiçÃo inseticidamente ativa
NO964472D0 (no) Halogenmetylamider som IL-1-prosteaseinhibirorer
ITMI940362A0 (it) Composizione antitosse
DE69616374D1 (de) Germizide zusammensetzung
FR2749162B1 (fr) Prothese cotyloidienne
FR2767673B1 (fr) Prothese uretrale
BR9607946A (pt) Composição
FI974086L (fi) Säätömenetelmä ja säätöjärjestely
FR2726464B3 (fr) Prothese vocale

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20150313